Volunteers from the Southampton area are being asked to sign up to the latest COVID-19 vaccine study to be rolled out across the UK.
The National Institute for Health Research (NIHR)-supported Valneva Phase 2/3 study is open to healthy adults who have not had a previous COVID-19 vaccine.
4,000 participants will be recruited across the UK, and everyone involved in the study will receive two active vaccine doses, administered in a four-week interval.
Those enrolled in the study over the age of 30 will be randomised to receive two doses of either the Valneva vaccine, or the approved Oxford/AstraZeneca vaccine.
Participants aged 18 – 29 can be enrolled into the study to receive the Valneva vaccine and will not be offered the approved Oxford/AstraZeneca vaccine.
Developed by the specialty vaccine company Valneva, the vaccine is being manufactured at the company’s site in Livingston, West Lothian, and is the only inactivated, adjuvanted (an ingredient to create a stronger immune response) COVID-19 vaccine in clinical development in Europe.
Volunteers for the study will be vaccinated at the beginning of May, and a proportion of potential participants will be identified through the NHS COVID-19 Vaccine Research Registry, which currently has over 480,000 sign ups. Subject to successful Phase 2/3 data, Valneva aims to make regulatory submissions for initial approval in the autumn of 2021.
If Valneva’s vaccine is shown to be safe and effective, up to 250 million vaccine doses could be supplied to the UK and other countries around the world. As part of the UK government’s vaccine procurement approach, up to 100 million doses of this vaccine have been secured.
Professor Saul Faust of the University of Southampton and the NIHR Southampton Clinical Research Facility, who is the local investigator for the trial said:
“Clinical studies into COVID-19 vaccines remain critical to help find several safe and effective candidates to help protect us all. Volunteers in Southampton are still needed to help carry out these studies. Visit the NHS website to sign up to be contacted about taking part in COVID-19 vaccine studies.”
Professor Adam Finn, Chief Investigator for the Valneva study said: “Following very encouraging safety and immune response results from our phase 1 study, along with my investigator colleagues, I am really looking forward to starting on this important next stage of the clinical development of this important new vaccine.
“We definitely need more vaccines to help us out of this pandemic and this one is a very promising candidate.”
Thomas Lingelbach, Chief Executive Officer of Valneva, said:
“As COVID-19 continues to impact people’s daily lives, Valneva remains fully focused on developing another safe and efficacious vaccine solution. The world needs multiple vaccines and we believe that ours has an important role to play – including boosters or potential modifications to address variants.
“The initiation of this trial marks a significant milestone in the development of the only inactivated vaccine candidate against COVID-19 in clinical trials in Europe. We are grateful to the NIHR for its continued support and to everyone who volunteers to make clinical trials possible.” Source: southampton.co.uk